Prospective Observational Study of Once-Daily Tamcontin® Tablet (Continus® Controlled release tablet of Tamsulosin Hydrochloride, 0.4 mg) in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (BPH) in the Routine Clinical Practice
Phase 4
- Conditions
- Health Condition 1: null- Condition: Benign Prostate Hyperplasia (BPH)Trial Participant: Newly diagnosed, treatment naive BPH patients eligible to receive Tamsulosin hydrochloride, 0.4 mg in the routine clinical practice
- Registration Number
- CTRI/2012/11/003151
- Lead Sponsor
- ModiMundiPharma Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Newly diagnosed, treatment naive BPH patients eligible to receive Tamsulosin hydrochloride, 0.4 mg in the routine clinical practice
Exclusion Criteria
Not Applicable
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method